Optometrists in New Haven, CT Accepting Medicare

21 Optometrists found. Showing 1 - 20

David W. Joel Llc Optometrist Medicare: Medicare Enrolled Practice Location: 130 Amity Rd, Family Eye Care Center, New Haven, CT 06515 Phone: 203-397-3878    Fax: 203-397-9110

Dr. Johnny Sun, OD Optometrist Medicare: Medicare Enrolled Practice Location: 400 Columbus Ave Fl 2, New Haven, CT 06519 Phone: 203-503-3230

Dr. Michelle Mitchell, OD Optometrist Medicare: Medicare Enrolled Practice Location: 130 Amity Rd, New Haven, CT 06515 Phone: 203-397-3878

Henry B Samson Optometrist Medicare: Not Enrolled in Medicare Practice Location: 100 York St, Suite 2k, New Haven, CT 06511 Phone: 203-624-3896

Dr. Andrew David Stack, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1457 Whalley Ave, New Haven, CT 06515 Phone: 203-387-3937    Fax: 203-389-3994

Dr. Vanessa Ann Tarud, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 330 Cedar St, New Haven, CT 06520 Phone: 386-341-2013

Dr. Leonard R Kauffman, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 130 Amity Rd, New Haven, CT 06515 Phone: 203-397-3878    Fax: 203-397-9110

Dr. Wendy Kok, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1457 Whalley Ave, New Haven, CT 06515 Phone: 203-562-3937

Dr. Peter L Jamison, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 60 Alston Ave, New Haven, CT 06515 Phone: 203-605-9573

Dr. Raymond Farmer, O.D Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1457 Whalley Ave, New Haven, CT 06515 Phone: 203-387-3937    Fax: 203-389-3994

David C Arendt, OD Optometrist Medicare: Medicare Enrolled Practice Location: 55 Lock Street, New Haven, CT 06520 Phone: 203-432-0076    Fax: 203-432-7289

Kennedy & Perkins, Inc. Optometrist Medicare: Medicare Enrolled Practice Location: 80 Whitney Ave, New Haven, CT 06510 Phone: 203-624-3145    Fax: 203-867-8733

Mark G Ryan Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1457 Whalley Ave, New Haven, CT 06515 Phone: 203-562-3937    Fax: 203-389-3994

Dr. Philip M Perrino, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 815 Chapel St, New Haven, CT 06510 Phone: 203-865-6727    Fax: 203-865-8040

Dr. Michael Demeo, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 80 Whitney Ave, New Haven, CT 06510 Phone: 203-624-3145    Fax: 203-867-8733

Dr. Larry Neil Spector, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 1044 Chapel St, New Haven, CT 06510 Phone: 203-787-7111    Fax: 203-787-3512

Henry B Samson, OD Optometrist Medicare: Medicare Enrolled Practice Location: 100 York St, Suite 2k, New Haven, CT 06511 Phone: 203-624-3896    Fax: 203-777-2020

Dr. David W. Joel, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 130 Amity Rd, New Haven, CT 06515 Phone: 203-397-3878    Fax: 203-397-9110

Dr. Erica Leigh Volker, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 40 Temple St, Suite 3a, New Haven, CT 06510 Phone: 203-785-2020

Myeyedr. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1457 Whalley Ave, New Haven, CT 06515 Phone: 203-387-3937

News Archive

Freezing or refrigerating expressed breast milk for longer than 48 hours substantially lowers its antioxidant content

This may be of particular importance for premature babies, who both have reduced antioxidant capacity as well as high levels of oxygen free radical activity as a result of infection and blood transfusions, say the authors.

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm's proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

Increased risk of cardiovascular problems can affect people with mild to moderate SDB: Research

Doctors have long known that snoring is hazardous to health for a number of reasons. In addition to restless nights and increased daytime sleepiness, sleep-disordered breathing has a series of associated health problems, including increased risk of cardiovascular disease. While it is not always clear what the association between SDB and a given health problem is, new research exposes that at least one factor may help to explain the increased risk of cardiovascular problems that affects even people with mild to moderate SDB.

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company's investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

Psychosocial risks experienced during adolescence may increase chance of HIV in adulthood

The psychological and social risks that adolescents experience can have a lasting impact on adulthood.

Read more Medical News

› Verified 4 days ago

• 1(current)
• 2